

FIRST QUARTER 2024 EARNINGS SUPPLEMENTAL

www.globalmedicalreit.com
NYSE: GMRE

TABLE OF CONTENTS





Company Overview	3
Select Quarterly Financial Data	6
Business Summary	7
Portfolio Summary	8
Key Tenants	11
Debt and Hedging Summary	12
Total Capitalization and Equity Summary	14
ESG Summary	15
Condensed Consolidated Statements of Operations	16
Condensed Consolidated Balance Sheets	17
Condensed Consolidated Statements of Cash Flows	18
Non-GAAP Reconciliations	19
Reporting Definitions and Other Disclosures	20


Forward-Looking Statements

Certain statements contained herein may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is the Company's intent that any such statements be protected by the safe harbor created thereby. These forward-looking statements are identified by their use of terms and phrases such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "plan," "predict," "project," "will," "continue" and other similar terms and phrases, including references to assumptions and forecasts of future results. Except for historical information, the statements set forth herein including, but not limited to, any statements regarding our earnings, our liquidity, our tenants' ability to pay rent to us, expected financial performance (including future cash flows associated with new tenants or the expansion of current properties), future dividends or other financial items; any other statements concerning our plans, strategies, objectives and expectations for future operations and future portfolio occupancy rates, our pipeline of acquisition opportunities and expected acquisition activity, including the timing and/or successful completion of any acquisitions and expected rent receipts on these properties, our expected disposition activity, including the timing and/or successful completion of any dispositions and the expected use of proceeds therefrom, and any statements regarding future economic conditions or performance are forward-looking statements. These forward-looking statements are based on our current expectations, estimates and assumptions and are subject to certain risks and uncertainties. Although the Company believes that the expectations, estimates and assumptions reflected in its forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of the Company's forward-looking statements. Additional information concerning us and our business, including additional factors that could materially and adversely affect our financial results, include, without limitation, the risks described under Part I, Item 1A - Risk Factors, in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and in our other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements. The Company does not intend, and undertakes no obligation, to update any forward-looking statement.

COMPANY OVERVIEW



GLOBAL MEDICAL REIT INC. (GMRE) IS A NET-LEASE MEDICAL REAL ESTATE INVESTMENT TRUST (REIT) THAT ACQUIRES HEALTHCARE FACILITIES AND LEASES THOSE FACILITIES TO PHYSICIAN GROUPS AND REGIONAL AND NATIONAL HEALTHCARE SYSTEMS.





PORTFOLIO SNAPSHOT (as of March 31, 2024)

Gross Investment in Real Estate (billions): \$1.4 Number of Buildings: 185 Number of States: 34 Weighted Average Portfolio Cap Rate: 7.9% % of Health System or Other Affiliated Tenants: 90% Weighted Average Lease Term (years): 5.8 Leased Occupancy: 96.4% Portfolio Rent Coverage: 4.8x

COMPANY OVERVIEW



Executive Officers

Jeffrey Busch Chairman, Chief Executive Officer and President

Robert Kiernan Chief Financial Officer and Treasurer

Alfonzo Leon Chief Investment Officer

Danica Holley Chief Operating Officer

Jamie Barber General Counsel and Corporate Secretary

Board of Directors

Jeffrey Busch Chairman, Chief Executive Officer and President

Henry Cole Lead Independent Director, Compensation Committee Chair,

Audit Committee Member

Paula Crowley Audit Committee Member, ESG Committee Member, Compensation

Committee Member

Matthew Cypher, Ph.D. ESG Committee Chair, Nominating and Corporate Governance

Committee Member

Ronald Marston Nominating and Corporate Governance Committee Chair,

Compensation Committee Member

Lori Wittman Audit Committee Chair, Nominating and Corporate Governance

Committee Member, ESG Committee Member

Zhang Huiqi Director

710/O INDEPENDENT DIRECTORS

BOARD % OF WOMEN

43%

COMPANY OVERVIEW



Corporate Headquarters

Global Medical REIT Inc. 7373 Wisconsin Avenue, Suite 800 Bethesda, MD 20814 Phone: 202.524.6851

www.globalmedicalreit.com

Stock Exchange

New York Stock Exchange

Ticker: GMRE

Investor Relations

Stephen Swett

Phone: 203.682.8377

Email: stephen.swett@icrinc.com

Independent Registered Public Accounting Firm

Deloitte & Touche LLP

McLean, VA

Corporate and REIT Tax Counsel

Vinson & Elkins LLP Daniel LeBey, Corporate Partner Christopher Mangin, REIT Tax Partner

Transfer Agent

Equiniti Trust Company Phone: 800.468.9716

Sell-Side Analyst Coverage

Firm Name

Baird Wes Golladay

BMO Juan Sanabria

B. Riley Securities Bryan Maher

Colliers Securities Barry Oxford

Compass Point Merrill Ross

JMP Securities Aaron Hecht

Janney Robert Stevenson

KeyBanc Austin Wurschmidt



SELECT QUARTERLY FINANCIAL DATA



(unaudited, and in thousands, except per share and unit amounts)

	March 31,	December 31,	September 30,	June 30,	March 31,
As of Period End (Unless Otherwise Specified)	2024	2023	2023	2023	2023
Market capitalization (common and OP)	\$593,521	\$752,680	\$608,247	\$619,096	\$612,165
Market price per share – common	\$8.75	\$11.10	\$8.97	\$9.13	\$9.11
Common shares and OP units outstanding	67,831	67,809	67,809	67,809	67,197
Preferred equity	\$74,959	\$74,959	\$74,959	\$74,959	\$74,959
Common equity	\$500,011	\$508,625	\$536,488	\$544,599	\$537,795
Noncontrolling interest	\$22,128	\$22,230	\$22,201	\$21,834	\$15,721
Total equity	\$597,098	\$605,814	\$633,648	\$641,392	\$628,475
Investment in real estate, gross	\$1,428,161	\$1,426,969	\$1,425,006	\$1,431,369	\$1,481,273
Borrowings:					
Credit Facility - revolver, gross	\$98,600	\$92,400	\$68,400	\$76,143	\$143,500
Credit Facility - term Ioan A, gross	\$350,000	\$350,000	\$350,000	\$350,000	\$350,000
Credit Facility - term loan B, gross	\$150,000	\$150,000	\$150,000	\$150,000	\$150,000
Notes payable, gross	\$25,735	\$25,965	\$57,160	\$57,496	\$57,780
Weighted average interest rate (for quarter)	3.90%	3.88%	3.98%	4.39%	4.27%
Debt covenants:					
Leverage ratio (as defined in Credit Facility)	44.0%	43.6%	44.2%	44.5%	47.4%
Fixed charge coverage ratio for quarter (1.50x minimum)	2.87	2.76	2.76	2.80	2.88
Fixed charge coverage ratio for quarter (1.50x minimum)	2.87 March 31,		2.76 September 30,	2.80 June 30 ,	2.88 March 31,
Fixed charge coverage ratio for quarter (1.50x minimum) Three Months Ended					
	March 31,	December 31,	September 30,	June 30,	March 31,
Three Months Ended	March 31, 2024	December 31, 2023	September 30, 2023	June 30, 2023	March 31, 2023
Three Months Ended Rental revenue	March 31, 2024 \$35,069	December 31, 2023 \$32,931	September 30, 2023 \$35,487 \$7,170	June 30, 2023 \$36,317	March 31, 2023 \$36,199
Three Months Ended Rental revenue Interest expense	March 31, 2024 \$35,069 \$6,890	December 31, 2023 \$32,931 \$6,984	September 30, 2023 \$35,487 \$7,170	June 30, 2023 \$36,317 \$8,468	March 31, 2023 \$36,199 \$8,271
Three Months Ended Rental revenue Interest expense General and administrative expenses	March 31, 2024 \$35,069 \$6,890 \$4,446	December 31, 2023 \$32,931 \$6,984 \$4,220	\$2023 \$35,487 \$7,170 \$4,367 \$14,195	June 30, 2023 \$36,317 \$8,468 \$4,462	March 31, 2023 \$36,199 \$8,271 \$3,804
Three Months Ended Rental revenue Interest expense General and administrative expenses Depreciation and amortization expense	March 31, 2024 \$35,069 \$6,890 \$4,446 \$14,084	December 31, 2023 \$32,931 \$6,984 \$4,220 \$14,245	\$2023 \$35,487 \$7,170 \$4,367 \$14,195 \$7,231	June 30, 2023 \$36,317 \$8,468 \$4,462 \$14,805	March 31, 2023 \$36,199 \$8,271 \$3,804 \$14,889
Three Months Ended Rental revenue Interest expense General and administrative expenses Depreciation and amortization expense Operating expenses	March 31, 2024 \$35,069 \$6,890 \$4,446 \$14,084 \$7,384	December 31, 2023 \$32,931 \$6,984 \$4,220 \$14,245 \$6,094	\$2023 \$35,487 \$7,170 \$4,367 \$14,195 \$7,231	June 30, 2023 \$36,317 \$8,468 \$4,462 \$14,805 \$7,223	March 31, 2023 \$36,199 \$8,271 \$3,804 \$14,889 \$7,536
Three Months Ended Rental revenue Interest expense General and administrative expenses Depreciation and amortization expense Operating expenses Total expenses	March 31, 2024 \$35,069 \$6,890 \$4,446 \$14,084 \$7,384 \$32,804	December 31, 2023 \$32,931 \$6,984 \$4,220 \$14,245 \$6,094	\$eptember 30, 2023 \$35,487 \$7,170 \$4,367 \$14,195 \$7,231 \$32,963	June 30, 2023 \$36,317 \$8,468 \$4,462 \$14,805 \$7,223 \$34,960	March 31, 2023 \$36,199 \$8,271 \$3,804 \$14,889 \$7,536 \$34,542
Three Months Ended Rental revenue Interest expense General and administrative expenses Depreciation and amortization expense Operating expenses Total expenses Gain on sale of investment properties	March 31, 2024 \$35,069 \$6,890 \$4,446 \$14,084 \$7,384 \$32,804	December 31, 2023 \$32,931 \$6,984 \$4,220 \$14,245 \$6,094 \$31,543	\$eptember 30, 2023 \$35,487 \$7,170 \$4,367 \$14,195 \$7,231 \$32,963	June 30, 2023 \$36,317 \$8,468 \$4,462 \$14,805 \$7,223 \$34,960	March 31, 2023 \$36,199 \$8,271 \$3,804 \$14,889 \$7,536 \$34,542
Three Months Ended Rental revenue Interest expense General and administrative expenses Depreciation and amortization expense Operating expenses Total expenses Gain on sale of investment properties Loss on extinguishment of debt	March 31, 2024 \$35,069 \$6,890 \$4,446 \$14,084 \$7,384 \$32,804	December 31, 2023 \$32,931 \$6,984 \$4,220 \$14,245 \$6,094 \$31,543	\$2023 \$35,487 \$7,170 \$4,367 \$14,195 \$7,231 \$32,963 \$2,289	June 30, 2023 \$36,317 \$8,468 \$4,462 \$14,805 \$7,223 \$34,960 \$12,786	March 31, 2023 \$36,199 \$8,271 \$3,804 \$14,889 \$7,536 \$34,542 \$485
Three Months Ended Rental revenue Interest expense General and administrative expenses Depreciation and amortization expense Operating expenses Total expenses Gain on sale of investment properties Loss on extinguishment of debt Net income (loss) attributable to common stockholders	March 31, 2024 \$35,069 \$6,890 \$4,446 \$14,084 \$7,384 \$32,804 - \$794	December 31, 2023 \$32,931 \$6,984 \$4,220 \$14,245 \$6,094 \$31,543 - (\$868) (\$840)	\$2023 \$35,487 \$7,170 \$4,367 \$14,195 \$7,231 \$32,963 \$2,289	June 30, 2023 \$36,317 \$8,468 \$4,462 \$14,805 \$7,223 \$34,960 \$12,786	March 31, 2023 \$36,199 \$8,271 \$3,804 \$14,889 \$7,536 \$34,542 \$485
Three Months Ended Rental revenue Interest expense General and administrative expenses Depreciation and amortization expense Operating expenses Total expenses Gain on sale of investment properties Loss on extinguishment of debt Net income (loss) attributable to common stockholders Net income (loss) per share	March 31, 2024 \$35,069 \$6,890 \$4,446 \$14,084 \$7,384 \$32,804 - - \$794 \$0.01	\$2023 \$32,931 \$6,984 \$4,220 \$14,245 \$6,094 \$31,543 - (\$868) (\$840) (\$0.01)	\$2023 \$35,487 \$7,170 \$4,367 \$14,195 \$7,231 \$32,963 \$2,289 - \$3,138 \$0.05	June 30, 2023 \$36,317 \$8,468 \$4,462 \$14,805 \$7,223 \$34,960 \$12,786 - \$11,820 \$0.18	March 31, 2023 \$36,199 \$8,271 \$3,804 \$14,889 \$7,536 \$34,542 \$485 - \$673 \$0.01
Three Months Ended Rental revenue Interest expense General and administrative expenses Depreciation and amortization expense Operating expenses Total expenses Gain on sale of investment properties Loss on extinguishment of debt Net income (loss) attributable to common stockholders Net income (loss) per share Wtd. avg. basic and diluted common shares (GAAP)	\$35,069 \$6,890 \$4,446 \$14,084 \$7,384 \$32,804 - - \$794 \$0.01 65,573	\$2023 \$32,931 \$6,984 \$4,220 \$14,245 \$6,094 \$31,543 - (\$868) (\$840) (\$0.01) 65,565	\$35,487 \$35,487 \$7,170 \$4,367 \$14,195 \$7,231 \$32,963 \$2,289 - \$3,138 \$0.05 65,565	June 30, 2023 \$36,317 \$8,468 \$4,462 \$14,805 \$7,223 \$34,960 \$12,786 - \$11,820 \$0.18 65,544	March 31, 2023 \$36,199 \$8,271 \$3,804 \$14,889 \$7,536 \$34,542 \$485 - \$673 \$0.01 65,525

\$0.23

70,757

\$0.23

70,565

AFFO per share and unit*

Wtd. avg. common shares, OP and LTIP units

\$0.23

69,830

\$0.23

70,434

\$0.23

70,566

BUSINESS SUMMARY



FIRST QUARTER 2024 OPERATING SUMMARY

- Net income attributable to common stockholders was \$0.8 million, or \$0.01 per diluted share, as compared to \$0.7 million, or \$0.01 per diluted share, in the comparable prior year period.
- Funds from Operations ("FFO") of \$14.9 million, or \$0.21 per share and unit, as compared to \$15.1 million, or \$0.22 per share and unit, in the comparable prior year period.
- Adjusted Funds from Operations ("AFFO") of \$16.5 million, or \$0.23 per share and unit, as compared to \$16.0 million, or \$0.23 per share and unit, in the comparable prior year period.
- Total revenue decreased to \$35.1 million as compared to \$36.2 million in the comparable prior year period, primarily reflecting the impact of the Company's property dispositions that were completed during 2023.

COMMON AND PREFERRED DIVIDENDS

- On March 7, 2024, the Board of Directors (the "Board") declared a:
 - \$0.21 per share cash dividend to common stockholders and unitholders of record as of March 22, 2024, which was paid on April 9, 2024; and
 - \$0.46875 per share cash dividend to holders of record as of April 15, 2024, of the Company's Series A Preferred Stock, which was paid on April 30, 2024.

INVESTMENT AND PORTFOLIO ACTIVITY

• In May, the Company entered into a purchase agreement to acquire a 15-property portfolio of outpatient medical real estate for an aggregate purchase price of \$81.3 million. The properties are fully occupied and leased under triple-net or absolute triple-net leases.

The Company expects to close this transaction in two tranches, with the first tranche (approximately \$30 million - \$35 million) closing during the third quarter of 2024 and the remainder closing during the fourth quarter of 2024. The Company's obligation to close the acquisition is subject to certain customary terms and conditions, including due diligence reviews. Accordingly, there is no assurance that the Company will close this acquisition on a timely basis, or at all.

- On May 6, 2024, one of the Company's tenants, Steward Health Care ("Steward"), announced that it filed for Chapter 11 bankruptcy reorganization. As of March 31, 2024, Steward represented 2.8% of the Company's annualized base rent, primarily in one facility located in Beaumont, Texas. Steward was current in its rental payments through February 2024 and as of March 31, 2024, the Company's receivable balance from Steward was \$0.5 million, including \$0.2 million of deferred rent.
- During the first quarter of 2024, the Company did not complete any acquisitions or dispositions.
- As of March 31, 2024, the Company's portfolio occupancy was 96.4%.

CAPITAL MARKETS AND DEBT ACTIVITY

- Leverage was 44.0% as of March 31, 2024.
- As of May 6, 2024, we had unutilized borrowing capacity under the Credit Facility of \$290 million.
- The Company did not issue any shares of common stock under its ATM program during the first quarter of 2024 or from April 1, 2024 through May 6, 2024.

PORTFOLIO SUMMARY

(as of March 31, 2024)



PORTFOLIO STATISTICS

Gross Investment in Real Estate (in billions)	\$1.4
Total Buildings	185
Total Leasable Square Feet (in millions)	4.8
Total Tenants	268
Leased Occupancy	96.4%
Total Annualized Base Rent (ABR) (in millions)	\$110.5
Portfolio Rent Coverage*	4.8x
Weighted Average Cap Rate	7.9%
Weighted Average Lease Term (years)	5.8
Weighted Average Rent Escalations	2.2%





TENANT COMPOSITION

	70 OI ADIN
Not-for-profit healthcare system	33%
For-profit healthcare system	28%
Other affiliated healthcare groups	29%
Total	90%

% of ARR

PORTFOLIO SUMMARY

(as of March 31, 2024)





LEASE TYPE

	<u>% of ABR</u>
Triple-net	55%
Absolute-net	37%
Modified gross	6%
Gross	2%

RENT COVERAGE*

Asset Type	% of ABR	<u>Ratio</u>
MOB	14%	6.6x
MOB/ASC	11%	5.0x
Inpatient Rehab (IRF)	17%	3.6x
Specialty Hospital ⁽¹⁾	6%	3.7x
Total/Weighted Average	48%	4.8x
Tenants Not Included		
Large/Credit Rated Tenants	31%	N/A
Not Reported	21%	N/A





¹⁾ Includes surgical hospitals, long-term acute care hospitals (LTACH) and behavioral hospitals.

PORTFOLIO SUMMARY


(as of March 31, 2024)








SPECIALTY BY ABR





Lease Expiration Schedule (ABR in thousands)					
		Leasable	% of Total Leasable		% of Total
Year	# of Leases	Square Feet	Square Feet	ABR	ABR
2024	55	515,997	10.9%	\$10,404	9.4%
2025	53	359,725	7.6%	\$7,926	7.2%
2026	70	519,350	10.9%	\$10,249	9.3%
2027	45	466,648	9.8%	\$11,645	10.5%
2028	35	349,656	7.4%	\$9,010	8.2%
2029	37	580,508	12.2%	\$14,731	13.3%
2030	28	394,995	8.3%	\$9,845	8.9%
2031	19	346,309	7.3%	\$7,624	6.9%
2032	6	72,284	1.5%	\$2,315	2.1%
2033	17	162,354	3.4%	\$4,253	3.8%
Thereafter	30	809,955	17.1%	\$22,478	20.4%
Total Leased SF	395	4,577,781	96.4%	\$110,480	100.0%
Current Vacancy		172,859	3.6%		
Total Leasable SF		4,750,640	100.0%		

KEY TENANTS



Asset Type

Lifepoint Health

LifePoint Health operates 62 community hospital campuses, more than 50 rehabilitation and behavioral health hospitals and more than 200 additional sites of care, including managed acute rehabilitation units, outpatient centers and post-acute care facilities.

IRF 7.0%

% of Portfolio ABR



Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States, with a national footprint that includes 153 hospitals in 36 states and Puerto Rico.

IRF 6.7%



MHS is the largest health system in the Parkersburg-Marietta-Vienna MSA and delivers healthcare services in southeast Ohio. MHS operates the 199-bed Marietta Memorial Hospital and two critical access hospitals, nine outpatient care centers, 26 medical staff offices, and clinical care delivery locations.

MOB 5.0%



Based in Charlotte, North Carolina, and formed from the combination of Advocate Aurora Health and Atrium Health, Advocate serves nearly 6 million patients annually and is the fifth-largest nonprofit integrated health system in the nation. With revenues of more than \$27 billion, the newly combined organization comprises more than 1,000

MOB 3.7%

sites of care and 67 hospitals.




Trinity Health is one of the largest not-for-profit, Catholic health care systems in the nation, with 88 hospitals, 135 continuing care locations, the second largest PACE program in the country, 136 urgent care locations and many other health and well-being services.

MOB 3.2%

DEBT AND HEDGING SUMMARY



Debt Statistics	As of March 31, 2024
Total Gross Debt (in thousands)	\$624,335
Fixed Rate Debt-to-Total Debt	84%
Weighted Average Interest Rate	3.85%
Weighted Average Maturity (Years)	2.7 years
Leverage Ratio	44.0%
Fixed Charge Coverage Ratio	2.87



Debt Detail (as of March 31, 2024)				
Debt	Balance (in thousands)	Rate Type	Interest Rate	Maturity
<u>Unsecured Credit Facility</u> :				
Revolver	\$98,600	Floating	SOFR + 1.35% ⁽¹⁾	8/1/2026 ⁽¹⁾
Term Loan A	\$350,000	Fixed	2.94% ⁽²⁾	May-26
Term Loan B	\$150,000	Fixed	4.00% ⁽²⁾	February-28
Other:				
Rosedale Loan	\$13,462	Fixed	3.85%	July-25
Dumfries Loan	\$10,957	Fixed	4.68%	June-24
Toledo Loan	\$1,316	Fixed	5.00%	July-33
Total/Weighted Average:	\$624,335		3.85%	2.7 years

⁽¹⁾ Credit spread of 1.35% is based on the Company's overall leverage ratio (as defined in the credit facility agreement) being between 40% and 45% at the end of the first quarter of 2024. Pursuant to the credit facility agreement, at each reporting date the credit spread will increase or decrease based on the Company's overall leverage ratio. In addition to the credit spread we also pay 10 bps related to the transition to the secured overnight financing rate (SOFR). The revolver has two Company-controlled, six-month extension options. If the Company exercises those options, the maturity date of the revolver would be August 2027.

⁽²⁾ Rates reflect the effect of the Company's interest rate swaps. See table on the next page for a detail of the Company's interest rate swaps. Consists of the fixed base rate plus a credit spread of 1.30% based on a leverage ratio of between 40% and 45% under our credit facility agreement, plus 10 bps related to the transition from LIBOR to SOFR and is calculated using 365/360 method.

DEBT AND HEDGING SUMMARY





Interest Rate Swap Detail (as of March 31, 2024) ⁽¹⁾			
Notional	Term	Weighted Average Interest Ra	tes
Term Loan A - \$350,000	Current – 8/2024	Fixed base rate:	1.50%
		Effective interest rate:	2.94% ⁽²⁾
	8/2024 – 4/2026	Fixed base rate:	1.36%
		Effective interest rate:	2.80% ⁽²⁾
Term Loan B - \$150,000	Current – 2/2028	Fixed base rate:	2.54%
		Effective interest rate:	4.00% ⁽²⁾

⁽¹⁾ Consists of a total of ten current interest rates swaps and three forward starting interest rate swaps whereby we pay (or will pay) the fixed base rate listed in the table above and receive the one-month SOFR, which is the reference rate for the outstanding loans in our credit facility.


⁽²⁾ Consists of the fixed base rate plus a credit spread of 1.30% based on a leverage ratio of between 40% and 45% under our credit facility agreement, plus 10 bps related to the transition from LIBOR to SOFR and is calculated using 365/360 method.

TOTAL CAPITALIZATION AND EQUITY SUMMARY



(unaudited, and in thousands, except per share data)

Total Capitalization	As of March 31, 2024
Total Gross Debt	\$624,335
Preferred Stock	\$74,959
Common Stock ⁽¹⁾	\$573,886
OP Units (2,244 units) ⁽¹⁾	\$19,635
Vested LTIP Units (2,403 units) ⁽²⁾	\$—
Total Capitalization	\$1,292,815



⁽¹⁾ Based on the closing price of the Company's common stock on March 28, 2024, of \$8.75 per share.

(2) LTIPs are issued as equity compensation to the Company's directors and employees and, as such, have no capital value associated to them.

Equity Detail					
Stock	Shares	Dividend Rate/Yield	Liquidation Preference	Optional Redemption Period	
Series A Cumulative Preferred Stock, \$0.001 par value per share	3,105	7.50%	\$25 per share	Began on 9/15/2022	
Common Stock, \$0.001 par value per share	65,587	9.60% ⁽¹⁾	N/A	N/A	

(1) Calculated by dividing the aggregate dividends received for the trailing four quarters of \$0.84 per share by the Company's closing stock price on March 28, 2024 of \$8.75 per share.

Preferred Dividends					
Record Date	Payment Date	Dividend (per share)			
7/15/2023	7/31/2023	\$0.46875			
10/15/2023	10/31/2023	\$0.46875			
1/15/2024	1/31/2024	\$0.46875			
4/15/2024	4/30/2024	\$0.46875			
	Total:	\$1.875			

Common Dividends					
Record Date	Payment Date	Dividend (per share)			
6/23/2023	7/11/2023	\$0.21			
9/22/2023	10/10/2023	\$0.21			
12/27/2023	1/9/2024	\$0.21			
3/22/2024	4/9/2024	\$0.21			
	Total:	\$0.84			

ESG SUMMARY



ENVIRONMENTAL

- We take climate change and the risks associated with climate change seriously—both physical and transitional. We
 utilized Moody's 427 Risk Management platform to help us identify and measure the potential climate risk
 exposure for our properties. The analysis summarizes the climate change-related risks, groups them by onset
 potential, and identifies opportunities for risk mitigation.
- We utilize the ENERGY STAR platform to collect and track our energy consumption data and have identified properties that are strong candidates for the ENERGY STAR certificate program. In 2022, we earned an ENERGY STAR certification for our Select Medical facility in Omaha, Nebraska, which scored 99, and for our Brown Clinic facility in Watertown, South Dakota, which attained a score of 84. In addition, in 2023, our facilities located in Dumfries, Virginia, Hialeah, Florida, and Dallas, Texas joined those in Omaha and Watertown as ENERGY STAR certificate recipients.
- We prioritize energy efficiency and sustainability when evaluating investment opportunities. We utilize utility and energy audits that are performed by third-party engineering consultants during the due diligence phase of our acquisitions. The energy consumption data that we collect is used to assess our facilities' carbon emission levels.
- We improved our overall GRESB score from 46 in 2022 to 54 for 2023. The scores reflect activity for the previous year. Since we began receiving a GRESB Assessment score in 2021, we have improved our score by 12 points.
- In the 2023 GRESB public disclosure assessment, GMRE ranked 4th of 10 in peer group. Fostering a resilient posture is essential to our business and we continue to explore methods to assess our climate-related risks and mitigate the impacts. For example, according to the 2023 GRESB assessment report for the risk management sector, GMRE received a score of 4.25/5 while the benchmark score was 3.97/5. In the performance sector of the Risk Assessment, GMRE received a score of 6.46/9 while the benchmark average was 5.66/9.
- In the second quarter of 2023 we published our 2022 corporate sustainability report, which can be found at https://www.globalmedicalreit.com/about/corporate-responsibility/.

SOCIAL

- Our Board continues to lead our social and governance efforts. With its diverse composition, our Board is a strong example of inclusive leadership with a composition of 43% women.
- Our commitment to employee engagement remains a high-priority, as we continue to make accommodations for health, safety, and work-life balance. With this commitment in mind, and with the compensation committee of the Board's leadership, we conducted an employee survey that covered a comprehensive range of subjects related to our employees' attitudes about our work culture and employee engagement.

GOVERNANCE

- The Board consists of a majority of independent directors and all standing Board committees are comprised of 100% independent directors.
- The Board formed a standing ESG committee that oversees the Company's environmental, social, governance and resilience efforts.
- The Company maintains comprehensive cyber-security incident prevention and response protocols which are overseen by the Audit Committee.
- The Company has adopted an executive incentive compensation clawback policy.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS



(unaudited, and in thousands, except per share amounts)

d in thousands, except per share amounts)	Three Months Ended		
	Ma	arch 31,	
	2024	2023	
Revenue			
Rental revenue	\$35,069	\$36,199	
Other income	49	31	
Total revenue	35,118	36,230	
Expenses			
General and administrative	4,446	3,804	
Operating expenses	7,384	7,536	
Depreciation expense	10,113	10,494	
Amortization expense	3,971	4,395	
Interest expense	6,890	8,271	
Preacquisition expense		42	
Total expenses	32,804	34,542	
Income before gain on sale of investment property	2,314	1,688	
Gain on sale of investment property		485	
Net income	\$2,314	\$2,173	
Less: Preferred stock dividends	(1,455)	(1,455)	
Less: Net income attributable to noncontrolling interest	(65)	(45)	
Net income attributable to common stockholders	\$794	\$673	
	¢0.04	60.04	
Net income attributable to common stockholders per share - basic and diluted	\$0.01	\$0.01	
Weighted average shares outstanding – basic and diluted	65,573	65,525	

CONDENSED CONSOLIDATED BALANCE SHEETS



unaudited, and in thousands)		As of	
	March 31, 2024	December 31, 2023	
Assets			
Investment in real estate:			
Land	\$164,315	\$164,315	
Building	1,036,224	1,035,705	
Site improvements	21,984	21,974	
Tenant improvements	67,021	66,358	
Acquired lease intangible assets	138,617	138,617	
	1,428,161	1,426,969	
Less: accumulated depreciation and amortization	(262,287)	(247,503)	
Investment in real estate, net	1,165,874	1,179,466	
Cash and cash equivalents	1,333	1,278	
Restricted cash	6,473	5,446	
Tenant receivables, net	7,743	6,762	
Due from related parties	363	193	
Escrow deposits	737	673	
Deferred assets	27,995	27,132	
Derivative asset	29,285	25,125	
Goodwill	5,903	5,903	
Other assets	17,874	15,722	
Total assets	\$1,263,580	\$1,267,700	
Liabilities and Equity			
Liabilities:			
Credit Facility, net	\$592,082	\$585,333	
Notes payable, net	25,682	25,899	
Accounts payable and accrued expenses	10,520	12,781	
Dividends payable	16,157	16,134	
Security deposits	4,376	3,688	
Other liabilities	12,952	12,770	
Acquired lease intangible liability, net	4,713	5,281	
Total liabilities	666,482	661,886	
Equity:			
Preferred stock (\$77,625 liquidation preference)	74,959	74,959	
Common stock	66	66	
Additional paid-in capital	722,623	722,418	
Accumulated deficit	(251,963)	(238,984)	
Accumulated other comprehensive income	29,285	25,125	
Total Global Medical REIT Inc. stockholders' equity	574,970	583,584	
Noncontrolling interest	22,128	22,230	
Total equity	597,098	605,814	
Total liabilities and equity	\$1,263,580	\$1,267,700	

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS



(unaudited, and in thousands) **Three Months Ended** March 31, 2024 2023 **Operating activities** Net income \$2,314 \$2,173 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation expense 10,113 10,494 Amortization of acquired lease intangible assets 3,863 4,373 Amortization of above market leases, net 251 291 Amortization of debt issuance costs and other 562 601 Stock-based compensation expense 1,233 688 Capitalized preacquisition and other costs charged to expense 34 15 Gain on sale of investment property (485)Other 169 Changes in operating assets and liabilities: (981)638 Tenant receivables Deferred assets (863)(811)Other assets and liabilities (1,033)(210)Accounts payable and accrued expenses (2,057)(1,223)Security deposits 688 (773)Net cash provided by operating activities 14,293 15,771 **Investing activities** Net proceeds from sale of investment property 4,175 Escrow deposits for purchase of properties (153)Advances made to related parties (170)(121)(809)Capital expenditures on existing real estate investments (2,004)**Leasing Commissions** (542)3,092 Net cash (used in) provided by investing activities (2,716)Financing activities Escrow deposits required by third party lenders (64)(639)Repayment of notes payable (230)(344)Proceeds from Credit Facility 14,000 12,600 Repayment of Credit Facility (7,800)(14,800)Dividends paid to common stockholders, and OP Unit and LTIP Unit holders (14,946)(14,699)Dividends paid to preferred stockholders (1,455)(1,455)(10,495)Net cash used in financing activities (19,337)Net increase (decrease) in cash and cash equivalents and restricted cash 1,082 (474)Cash and cash equivalents and restricted cash—beginning of period 6,724 14,455

Cash and cash equivalents and restricted cash—end of period

\$13,981

\$7,806

NON-GAAP RECONCILIATIONS

GLOBAL MEDICAL REIT

(unaudited, and in thousands, except per share and unit amounts)

	Three Months Ended				
	March 31,	December 31,	September 30,	June 30,	March 31,
FFO and AFFO	2024	2023	2023	2023	2023
Net income	\$2,314	\$551	\$4,833	\$14,177	\$2,173
Less: Preferred stock dividends	(1,455)	(1,455)	(1,455)	(1,455)	(1,455)
Depreciation and amortization expense	14,024	14,211	14,161	14,774	14,861
Gain on sale of investment properties			(2,289)	(12,786)	(485)
FFO	\$14,883	\$13,307	\$15,250	\$14,710	\$15,094
Loss on extinguishment of debt	_	868	_	_	_
Amortization of above market leases, net	251	240	234	287	291
Straight line deferred rental revenue	(400)	(273)	(721)	(879)	(763)
Stock-based compensation expense	1,233	1,222	1,185	1,147	688
Amortization of debt issuance costs and other	562	581	593	601	601
Preacquisition expense				2	42
AFFO	\$16,529	\$15,945	\$16,541	\$15,868	\$15,953
Net income attributable to common	Ć0 04	(40.04)	Ć0.05	Ć0 40	ć0.01
stockholders per share – basic and diluted	\$0.01	(\$0.01)	\$0.05	\$0.18	\$0.01
FFO per share and unit	\$0.21	\$0.19	\$0.22	\$0.21	\$0.22
AFFO per share and unit	\$0.23	\$0.23	\$0.23	\$0.23	\$0.23
Wtd Average Common Shares, OP and LTIP Units outstanding:					
Common shares	65,573	65,565	65,565	65,544	65,525
OP units	2,244	2,244	2,244	2,134	1,667
LTIP units	2,940	2,756	2,757	2,747	2,638
Wtd Average Common Shares, OP and LTIP Units Outstanding - basic and diluted	70,757	70,565	70,566	70,434	69,830

	Three Months Ended				
	March 31,	December 31,	September 30,	June 30,	March 31,
EBITDAre and Adjusted EBITDAre	2024	2023	2023	2023	2023
Net income	\$2,314	\$551	\$4,833	\$14,177	\$2,173
Interest expense	6,890	6,984	7,170	8,468	8,271
Depreciation and amortization expense	14,084	14,245	14,195	14,805	14,889
Gain on sale of investment properties	_	_	(2,289)	(12,786)	(485)
EBITDA <i>re</i>	\$23,288	\$21,780	\$23,909	\$24,664	\$24,848
Loss on extinguishment of debt	_	868	_	_	_
Stock-based compensation expense	1,233	1,222	1,185	1,147	688
Amortization of above market leases, net	251	240	234	287	291
Preacquisition expense				2	42
Adjusted EBITDA <i>re</i>	\$24,772	\$24,110	\$25,328	\$26,100	\$25,869

REPORTING DEFINITIONS AND OTHER DISCLOSURES



Annualized Base Rent

Annualized base rent represents monthly base rent for March 2024, multiplied by 12 (or base rent net of annualized expenses for properties with gross leases). Accordingly, this methodology produces an annualized amount as of a point in time but does not take into account future (i) contractual rental rate increases, (ii) leasing activity or (iii) lease expirations. Additionally, leases that are accounted for on a cash-collected basis are not included in annualized base rent.

Capitalization Rate

The capitalization rate ("Cap Rate") for an acquisition is calculated by dividing current Annualized Base Rent by contractual purchase price. For the portfolio capitalization rate, certain adjustments, including for subsequent capital invested, are made to the contractual purchase price.

Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate ("EBITDAre" and "Adjusted EBITDAre")We calculate EBITDAre in accordance with standards established by NAREIT and define EBITDAre as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, gain or loss on the sale of investment properties, and impairment loss, as applicable.

We define Adjusted EBITDAre as EBITDAre plus loss on the extinguishment of debt, non-cash stock compensation expense, non-cash intangible amortization related to above and below market leases, preacquisition expense and other normalizing items. Management considers EBITDAre and Adjusted EBITDAre important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.

Funds from Operations and Adjusted Funds from Operations

Funds from operations ("FFO") and adjusted funds from operations ("AFFO") are non-GAAP financial measures within the meaning of the rules of the SEC. The Company considers FFO and AFFO to be important supplemental measures of its operating performance and believes FFO is frequently used by securities analysts, investors, and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results.

In accordance with the National Association of Real Estate Investment Trusts' ("NAREIT") definition, FFO means net income or loss computed in accordance with GAAP before noncontrolling interests of holders of OP units and LTIP units, excluding gains (or losses) from sales of property and extraordinary items, less preferred stock dividends, plus real estate-related depreciation and amortization (excluding amortization of debt issuance costs and the amortization of above and below market leases), and after adjustments for unconsolidated partnerships and joint ventures. Because FFO excludes real estate-related depreciation and amortization (other than amortization of debt issuance costs and above and below market lease amortization expense), the Company believes that FFO provides a performance measure that, when compared period-over-period, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from the closest GAAP measurement, net income or loss.

AFFO is a non-GAAP measure used by many investors and analysts to measure a real estate company's operating performance by removing the effect of items that do not reflect ongoing property operations. Management calculates AFFO by modifying the NAREIT computation of FFO by adjusting it for certain cash and non-cash items and certain recurring and non-recurring items. For the Company these items include recurring acquisition and disposition costs, loss on the extinguishment of debt, recurring straight line deferred rental revenue, recurring stock-based compensation expense, recurring amortization of above and below market leases, recurring amortization of debt issuance costs, and other items.

Management believes that reporting AFFO in addition to FFO is a useful supplemental measure for the investment community to use when evaluating the operating performance of the Company on a comparative basis.

REPORTING DEFINITIONS AND OTHER DISCLOSURES



Rent Coverage Ratio

For purposes of calculating our portfolio weighted-average EBITDARM coverage ratio ("Rent Coverage Ratio"), we excluded credit-rated tenants or their subsidiaries for which financial statements were either not available or not sufficiently detailed. These ratios are based on the latest available information only. Most tenant financial statements are unaudited and we have not independently verified any tenant financial information (audited or unaudited) and, therefore, we cannot assure you that such information is accurate or complete. Certain other tenants (approximately 21% of our portfolio) are excluded from the calculation due to (i) lack of available financial information or (ii) small tenant size. Additionally, included within 21% of non-reporting tenants is Pipeline Healthcare, LLC, which was sold to Heights Healthcare in October 2023 and is being operated under new management. Additionally, our Rent Coverage Ratio adds back physician distributions and compensation. Management believes all adjustments are reasonable and necessary.

Other Disclosures

Non-GAAP Financial Measures

Management considers certain non-GAAP financial measures to be useful supplemental measures of the Company's operating performance. For the Company, non-GAAP measures consist of EBITDAre, Adjusted EBITDAre, FFO and AFFO. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. The Company reports non-GAAP financial measures because these measures are observed by management to also be among the most predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these non-GAAP financial measures.

The non-GAAP financial measures presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented elsewhere herein.

Additional Information

The information in this document should be read in conjunction with the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other information filed with, or furnished to, the SEC. You can access the Company's reports and amendments to those reports filed or furnished to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act in the "Investor Relations" section on the Company's website (www.globalmedicalreit.com) under "SEC Filings" as soon as reasonably practicable after they are filed with, or furnished to, the SEC. The information on or connected to the Company's website is not, and shall not be deemed to be, a part of, or incorporated into, this Earnings Supplemental. You also can review these SEC filings and other information by accessing the SEC's website at http://www.sec.gov.

Certain information contained in this package, including, but not limited to, information contained in our Top 10 tenant profiles is derived from publicly-available third-party sources. The Company has not independently verified this information and there can be no assurance that such information is accurate or complete.



INVESTOR RELATIONS

Stephen Swett 203.682.8377 stephen.swett@icrinc.com

globalmedicalreit.com
NYSE: GMRE



